Dodecyl beta-D-maltoside

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Dodecyl beta-D-maltoside
• 英文别名: 2-[6-dodecoxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₂₄H₄₆O₁₁
• 分子量: 510.6
• InChiKey: NLEBIOOXCVAHBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  35
• 可旋转键数：
  16
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  179
• 氢给体数：
  7
• 氢受体数：
  11

文献信息

• Peptide pharmaceuticals
  申请人：Nestor John J.

  公开号：US10010617B2

  公开（公告）日：2018-07-03

  Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

  本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可改善基于肽和蛋白质的疗法的药物特性。
• Peptide pharmaceuticals for insulin resistance
  申请人：Nestor John J.

  公开号：US10471127B2

  公开（公告）日：2019-11-12

  Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

  本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可改善基于肽和蛋白质的疗法的药物特性。
• HEMOLYSIS REAGENT COMPOSITION FOR HEMOGLOBIN A1C QUANTITATIVE ANALYSIS USING ENZYMATIC METHOD
  申请人：i-Sens, Inc.

  公开号：EP2813854B1

  公开（公告）日：2016-09-07
• PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
  申请人：SPITFIRE PHARMA, INC.

  公开号：US20180194826A1

  公开（公告）日：2018-07-12

  Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
• METHODS AND SYSTEMS FOR IMPROVED DROPLET STABILIZATION
  申请人：10X GENOMICS, INC.

  公开号：US20200188920A1

  公开（公告）日：2020-06-18

  The present disclosure provides methods for forming emulsions. A method for forming an emulsion comprises: bringing a first fluid phase in contact with a second fluid phase that is immiscible with the first fluid phase to generate the emulsion comprising the plurality of droplets. The plurality of droplets may comprise (i) the first fluid phase or the second fluid phase, (ii) a first surfactant at an interface between the first fluid phase and the second fluid phase, and (iii) a second surfactant that is different than the first surfactant. Subsequent to generating the emulsion, collect or direct the plurality of droplets along a channel. Subsequent to collecting or directing the plurality of droplets along the channel, at most 5% of the plurality of droplets coalesce.